Clinical Trials

25 enrolled

Phase 3 Active not recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT03271372 2026-04-13

ADAM

101 enrolled

Carcinoma, Merkel Cell

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

24 enrolled

Breast Neoplasms

NCT04291885 2026-04-09

I-MAT

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04841148 2026-04-09

PALAVY

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

18 enrolled

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04261855 2026-03-27

GoTHAM

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Phase 3 Active not recruiting

Skin Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03573648 2026-03-19

ImmunoADAPT

33 enrolled

Breast Neoplasms

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT04004442 2026-03-13

COAXIN

19 enrolled

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07460245 2026-03-10

AVESEC

144 enrolled

Carcinoma, Transitional Cell

NCT03719768 2026-03-02

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

16 enrolled

CNS

Brain Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03006848 2026-02-23

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

19 enrolled 11 charts

Sarcoma

Osteosarcoma

NCT03252938 2026-02-19

INSIGHT

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Phase EARLY_PHASE1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

60 enrolled

Skin Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

9 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Neoplasms

NCT03744793 2026-01-09

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

18 enrolled

Carcinoma, Transitional Cell

NCT06518564 2026-01-07

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

25 enrolled

Gynecologic

Endometrial Neoplasms

NCT03391479 2025-12-18

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

25 enrolled

Neoplasm Metastasis, Penile Neoplasms

NCT02926196 2025-12-12

A-Brave

Phase 3 Completed

474 enrolled

Triple Negative Breast Neoplasms

NCT04188119 2025-12-08

IMpALA

Phase 2 Withdrawn

Breast Neoplasms

NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

21 enrolled

Carcinoma, Transitional Cell

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Recruiting

1,220 enrolled

Carcinoma, Renal Cell

NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

23 enrolled 11 charts

Neoplasm Metastasis

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2 Terminated

14 enrolled 14 charts

Urinary Bladder Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

173 enrolled 28 charts

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Neoplasm Metastasis, Prostatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

220 enrolled 11 charts

Breast Neoplasms

NCT04678362 2025-09-22

TALASUR

50 enrolled

Carcinoma, Transitional Cell

NCT04258956 2025-09-11

AXAGIST

58 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04242238 2025-08-28

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

32 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04341181 2025-07-25

ProTarget

300 enrolled

Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

106 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

100 enrolled 15 charts

Breast Neoplasms

NCT03186326 2025-06-29

SAMCO

132 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03357757 2025-06-26

LATENT

Phase 3 Active not recruiting

39 enrolled

GastrointestinalLymphoid

Cancer That is Associated With a Chronic Viral Infection

NCT03826589 2025-06-11

ALARICE

Phase NA Completed

23 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02999087 2025-05-07

REACH

707 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03971409 2025-05-02

InCITe

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

57 enrolled

Neoplasms, Second Primary

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03440567 2025-03-26

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

16 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06892860 2025-03-25

DISCUS

320 enrolled